TelecomMedia & EntertainmentHealthcareManufacturingClimate & EnergyEducationFintechE-Commerce & MarketplaceConsumer
CDH Investments is a major Chinese alternative asset management firm based in Beijing, founded in 2002 as a spin-off from CICC. The firm invests across private equity, venture capital, private credit, public equities, and real assets, with over $20 billion in assets under management.
Deal activity decreased year-over-year (1 deal in the last 12 months vs 4 prior). Average disclosed round size is $251.1M (across 64 rounds with reported amounts).
Portfolio
46
Fund Size
$1.5B
Top Stage
Series B
Last 12 Mo
1
Team
WM
Wang Mei
Head of RAManaging Partner
WL
Wang Lin
Managing PartnerVenture and Growth Capital
HX
Hu Xiaoling
Managing PartnerPrivate Equity
LG
LI Gang
Executive ChairmanCephei Capital
WS
Wu Shangzhi
Chairman
YW
Ying Wei
Managing PartnerBaifu
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
80 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| AAisphere | Series C | — | Jul 2026 |
| AAishi Technology | Series C | $300M | Mar 2026 |
| II-space | Series E | — | Feb 2026 |
| EEven Realities | Series B | $150M | Jan 2026 |
 AusperBio | Series C | $120M | Jan 2026 |
| AusperBio | Series B | $63M | Sep 2025 |
| RRobot Era | Series A | $42.2M | Jul 2025 |
| AusperBio | Series B | $50M | May 2025 |
| RRobot Era | Series A | $69M | Jan 2025 |
 Zelos | Series B | $100M | Jan 2025 |
| AusperBio | Series B | $73M | Dec 2024 |
| SSpear Bio | Series A | $45M | Jul 2024 |
 ReviR Therapeutics | Series A | $30M | Jul 2024 |
| RRevir | Series A | $30M | Jul 2024 |
| EEven Realities | Series A | — | Jan 2024 |
| MMayfair | Seed | $8M | Apr 2022 |
| RRevir | Seed | $20M | Jan 2022 |
| ReviR Therapeutics | Seed | $20M | Jan 2022 |
 GemPharmatech | Ipo | $175M | Jan 2022 |
| RRuigu | Seed | $400M | Jan 2022 |
| GGenFleet | Series C | $75M | Dec 2021 |
 ForwardX | Series C | $31M | Dec 2021 |
| RRuigu | Series D | $250M | Oct 2021 |
 Iaso Biotherapeutics | Series C | $108M | Sep 2021 |
| IInnovative Cellular Therapeutics | Series C | $40M | Sep 2021 |
Page 1 of 4
Top Co-Investors
Source Code Capital10 shared
Hillhouse Investment9 shared
IDG Capital8 shared
LAV6 shared
HongShan6 shared
Alibaba Group Holding Ltd.6 shared
Ally Bridge Group5 shared
Hankang Capital5 shared
YuanBio Venture Capital5 shared
Lake Bleu Capital5 shared
Shunwei Capital4 shared
EDBI4 shared
Hopu Investments4 shared
5Y Capital4 shared
Sky9 Capital4 shared
GLP4 shared
Primavera Capital Group4 shared
K2VC4 shared
Yunfeng Capital4 shared
Dyee Capital4 shared
Last updated: 20 October 2026